Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Randomised, Observer-blind, Placebo-controlled, Multi-centre Study to Evaluate the Efficacy, Immunogenicity and Safety of the Adjuvanted SARS-CoV-2 Subunit Vaccine in Adults Aged 18 Years and Above

Next Previous
X
Search
Trial Profile

A Phase 2/3 Randomised, Observer-blind, Placebo-controlled, Multi-centre Study to Evaluate the Efficacy, Immunogenicity and Safety of the Adjuvanted SARS-CoV-2 Subunit Vaccine in Adults Aged 18 Years and Above

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II/III

Latest Information Update: 31 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs UQ CSL V451 (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Sponsors Seqirus

    • Most Recent Events

    • 24 Mar 2021 According to ClinicalTrial.gov record, Seqirus discontinued V451_07 Phase 2 start-up activities prior to enrolling subjects. Data from Phase 1 did not support further development.
    • 27 Oct 2020 New trial record
    • 08 Sep 2020 According to a CSL media release, the company will take full responsibility for this study. This study is expected to initiate in late 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top